Effects Of Pioglitazone On Patients With Ischemic Stroke As An Add-On Treatment

The Effect of Pioglitazone as Add-On Therapy on NIH Stroke Scale Scores in Patients with Ischemic Stroke: A Randomized Placebo-Controlled Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20241220064106N1

Enrollment

Registered

2025-05-07

Start date

2025-03-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke, NIH stroke score.

Interventions

Intervention 1: Intervention group 1: Ischemic stroke patients eligible for thrombolytic therapy who received adjunctive treatment with pioglitazone. Intervention 2: Intervention group 2: Stroke patie

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Transient ischemic attack or acute ischemic stroke within the past 24 hours.

Exclusion criteria

Exclusion criteria: Patients with heart failure Use of medications affecting the metabolism of pioglitazone or the presence of active liver or kidney disease Pregnancy Patients who underwent thrombectomy Obesity Peripheral edema Bone fracture

Design outcomes

Primary

Measure	Time frame
National Institutes of Health Stroke Scale (NIHSS). Timepoint: Calculation of "National Institutes of Health Stroke Scale (NIHSS)" before the intervention and five days after the intervention. Method of measurement: National Institutes of Health Stroke Scale (NIHSS) checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Khazaei

Hamedan University of Medical Sciences

m.khazaei@umsha.ac.ir+98 81 3838 0572

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026